Development of a new conceptual platform in asthmology. EAACI 2018

Asthma remains one of the most important medical and social problems of current medicine. Despite significant approaches the increase in its incidence continues. 334 million people worldwide are affected by this chronic disease and more than 250 thousand die every year. Current asthma treatment methods aren’t useful to achieve asthma control in half of patients that associates with high risk of exacerbation of the disease. Modern asthma management requires a deep analysis of the factors responsible for the asthma progression and the development of exacerbations. The European Academy of Allergology and Clinical Immunology was held May 26-30, 2018 in Munich. The present publication sums up speeches of leading experts in the field of allergology and clinical immunology. Well-known experts in the field of diagnostics, treatment, prevention of bronchial asthma, modern views on the problem, a common pathology, which, despite considerable efforts, continues to grow, especially in the children’s population. The use of recent advances in molecular allergology, clinical immunology makes it possible to convincingly prove the heterogeneity of bronchial asthma, the need to use new diagnostic and therapeutic methods: biomarkers to detect pheno-endotypic diseases with the appointment of strictly targeted individualized treatment of patients with the results of new biologics. All attention was paid to the study of emerging and clinical trends of uncontrolled bronchial asthma, proposals for the use of new classification structures with indication of biological markers of each pheno-endotype of uncontrolled bronchial asthma were considered. A revised version of the GINA with the revision of therapeutic tactics, including in children, is presented. The latest EAACI Congress made a significant contribution to improving the diagnosis and effective treatment of bronchial asthma, which will allow treating patients with different clinical manifestations of this disease.